Acerus Pharmaceuticals and its subsidiaries, Acerus Biopharma, Acerus Labs and Acerus Pharmaceuticals USA, have received an order for creditor protection from the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (the CCAA).